Market Analysis and Insights: Global Alpha- Antitrypsin Deficiency Treatment Market
The research report studies the Alpha- Antitrypsin Deficiency Treatment market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Alpha- Antitrypsin Deficiency Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Alpha- Antitrypsin Deficiency Treatment Scope and Segment
The global Alpha- Antitrypsin Deficiency Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Alpha- Antitrypsin Deficiency Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others
by Application, this report covers the following segments
Clinic
Hospital
Others
Global Alpha- Antitrypsin Deficiency Treatment market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Alpha- Antitrypsin Deficiency Treatment key players in this market include:
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
The research report studies the Alpha- Antitrypsin Deficiency Treatment market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Alpha- Antitrypsin Deficiency Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Alpha- Antitrypsin Deficiency Treatment Scope and Segment
The global Alpha- Antitrypsin Deficiency Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Alpha- Antitrypsin Deficiency Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others
by Application, this report covers the following segments
Clinic
Hospital
Others
Global Alpha- Antitrypsin Deficiency Treatment market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Alpha- Antitrypsin Deficiency Treatment key players in this market include:
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
1 Market Overview of Alpha- Antitrypsin Deficiency Treatment
1.1 Alpha- Antitrypsin Deficiency Treatment Market Overview
1.1.1 Alpha- Antitrypsin Deficiency Treatment Product Scope
1.1.2 Alpha- Antitrypsin Deficiency Treatment Market Status and Outlook
1.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2016-2027)
1.4 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Region (2016-2021)
1.5 Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Alpha- Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.2 Europe Alpha- Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.3 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.4 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.5 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size (2016-2027)
2 Alpha- Antitrypsin Deficiency Treatment Market Overview by Type
2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Type (2016-2021)
2.3 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Type (2022-2027)
2.4 CT-2009
2.5 POL-6014
2.6 ARO-AAT
2.7 ALNAAT-02
2.8 Others
3 Alpha- Antitrypsin Deficiency Treatment Market Overview by Application
3.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Application (2016-2021)
3.3 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Application (2022-2027)
3.4 Clinic
3.5 Hospital
3.6 Others
4 Alpha- Antitrypsin Deficiency Treatment Competition Analysis by Players
4.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2020)
4.3 Date of Key Players Enter into Alpha- Antitrypsin Deficiency Treatment Market
4.4 Global Top Players Alpha- Antitrypsin Deficiency Treatment Headquarters and Area Served
4.5 Key Players Alpha- Antitrypsin Deficiency Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Alpha- Antitrypsin Deficiency Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Adverum Biotechnologies Inc.
5.1.1 Adverum Biotechnologies Inc. Profile
5.1.2 Adverum Biotechnologies Inc. Main Business
5.1.3 Adverum Biotechnologies Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.1.4 Adverum Biotechnologies Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.1.5 Adverum Biotechnologies Inc. Recent Developments
5.2 Alnylam Pharmaceuticals Inc.
5.2.1 Alnylam Pharmaceuticals Inc. Profile
5.2.2 Alnylam Pharmaceuticals Inc. Main Business
5.2.3 Alnylam Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.2.4 Alnylam Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.2.5 Alnylam Pharmaceuticals Inc. Recent Developments
5.3 Applied Genetic Technologies Corporation
5.3.1 Applied Genetic Technologies Corporation Profile
5.3.2 Applied Genetic Technologies Corporation Main Business
5.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.3.4 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.3.5 Arrowhead Pharmaceuticals Inc. Recent Developments
5.4 Arrowhead Pharmaceuticals Inc.
5.4.1 Arrowhead Pharmaceuticals Inc. Profile
5.4.2 Arrowhead Pharmaceuticals Inc. Main Business
5.4.3 Arrowhead Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.4.4 Arrowhead Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.4.5 Arrowhead Pharmaceuticals Inc. Recent Developments
5.5 Carolus Therapeutics Inc.
5.5.1 Carolus Therapeutics Inc. Profile
5.5.2 Carolus Therapeutics Inc. Main Business
5.5.3 Carolus Therapeutics Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.5.4 Carolus Therapeutics Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.5.5 Carolus Therapeutics Inc. Recent Developments
5.6 Cevec Pharmaceuticals GmbH
5.6.1 Cevec Pharmaceuticals GmbH Profile
5.6.2 Cevec Pharmaceuticals GmbH Main Business
5.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.6.4 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.6.5 Cevec Pharmaceuticals GmbH Recent Developments
5.7 Dicerna Pharmaceuticals Inc.
5.7.1 Dicerna Pharmaceuticals Inc. Profile
5.7.2 Dicerna Pharmaceuticals Inc. Main Business
5.7.3 Dicerna Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.7.4 Dicerna Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.7.5 Dicerna Pharmaceuticals Inc. Recent Developments
5.8 Digna Biotech, S.L.
5.8.1 Digna Biotech, S.L. Profile
5.8.2 Digna Biotech, S.L. Main Business
5.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.8.4 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.8.5 Digna Biotech, S.L. Recent Developments
5.9 Editas Medicine Inc.
5.9.1 Editas Medicine Inc. Profile
5.9.2 Editas Medicine Inc. Main Business
5.9.3 Editas Medicine Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.9.4 Editas Medicine Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.9.5 Editas Medicine Inc. Recent Developments
5.10 Grifols, S.A.
5.10.1 Grifols, S.A. Profile
5.10.2 Grifols, S.A. Main Business
5.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.10.4 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.10.5 Grifols, S.A. Recent Developments
5.11 Inhibrx
5.11.1 Inhibrx Profile
5.11.2 Inhibrx Main Business
5.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.11.4 Inhibrx Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.11.5 Inhibrx Recent Developments
5.12 Intellia Therapeutics Inc.
5.12.1 Intellia Therapeutics Inc. Profile
5.12.2 Intellia Therapeutics Inc. Main Business
5.12.3 Intellia Therapeutics Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.12.4 Intellia Therapeutics Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.12.5 Intellia Therapeutics Inc. Recent Developments
5.13 International Stem Cell Corporation
5.13.1 International Stem Cell Corporation Profile
5.13.2 International Stem Cell Corporation Main Business
5.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.13.4 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.13.5 International Stem Cell Corporation Recent Developments
5.14 Ionis Pharmaceuticals Inc.
5.14.1 Ionis Pharmaceuticals Inc. Profile
5.14.2 Ionis Pharmaceuticals Inc. Main Business
5.14.3 Ionis Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.14.4 Ionis Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.14.5 Ionis Pharmaceuticals Inc. Recent Developments
5.15 Kamada Ltd.
5.15.1 Kamada Ltd. Profile
5.15.2 Kamada Ltd. Main Business
5.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.15.4 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.15.5 Kamada Ltd. Recent Developments
5.16 Polyphor Ltd.
5.16.1 Polyphor Ltd. Profile
5.16.2 Polyphor Ltd. Main Business
5.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.16.4 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.16.5 Polyphor Ltd. Recent Developments
5.17 ProMetic Life Sciences Inc.
5.17.1 ProMetic Life Sciences Inc. Profile
5.17.2 ProMetic Life Sciences Inc. Main Business
5.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.17.4 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.17.5 ProMetic Life Sciences Inc. Recent Developments
5.18 rEVO Biologics Inc.
5.18.1 rEVO Biologics Inc. Profile
5.18.2 rEVO Biologics Inc. Main Business
5.18.3 rEVO Biologics Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.18.4 rEVO Biologics Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.18.5 rEVO Biologics Inc. Recent Developments
5.19 Sangamo BioSciences Inc.
5.19.1 Sangamo BioSciences Inc. Profile
5.19.2 Sangamo BioSciences Inc. Main Business
5.19.3 Sangamo BioSciences Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.19.4 Sangamo BioSciences Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.19.5 Sangamo BioSciences Inc. Recent Developments
6 North America
6.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Alpha- Antitrypsin Deficiency Treatment Market Dynamics
11.1 Alpha- Antitrypsin Deficiency Treatment Industry Trends
11.2 Alpha- Antitrypsin Deficiency Treatment Market Drivers
11.3 Alpha- Antitrypsin Deficiency Treatment Market Challenges
11.4 Alpha- Antitrypsin Deficiency Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
1.1 Alpha- Antitrypsin Deficiency Treatment Market Overview
1.1.1 Alpha- Antitrypsin Deficiency Treatment Product Scope
1.1.2 Alpha- Antitrypsin Deficiency Treatment Market Status and Outlook
1.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2016-2027)
1.4 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Region (2016-2021)
1.5 Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Alpha- Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.2 Europe Alpha- Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.3 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.4 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.5 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size (2016-2027)
2 Alpha- Antitrypsin Deficiency Treatment Market Overview by Type
2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Type (2016-2021)
2.3 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Type (2022-2027)
2.4 CT-2009
2.5 POL-6014
2.6 ARO-AAT
2.7 ALNAAT-02
2.8 Others
3 Alpha- Antitrypsin Deficiency Treatment Market Overview by Application
3.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Application (2016-2021)
3.3 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Application (2022-2027)
3.4 Clinic
3.5 Hospital
3.6 Others
4 Alpha- Antitrypsin Deficiency Treatment Competition Analysis by Players
4.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2020)
4.3 Date of Key Players Enter into Alpha- Antitrypsin Deficiency Treatment Market
4.4 Global Top Players Alpha- Antitrypsin Deficiency Treatment Headquarters and Area Served
4.5 Key Players Alpha- Antitrypsin Deficiency Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Alpha- Antitrypsin Deficiency Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Adverum Biotechnologies Inc.
5.1.1 Adverum Biotechnologies Inc. Profile
5.1.2 Adverum Biotechnologies Inc. Main Business
5.1.3 Adverum Biotechnologies Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.1.4 Adverum Biotechnologies Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.1.5 Adverum Biotechnologies Inc. Recent Developments
5.2 Alnylam Pharmaceuticals Inc.
5.2.1 Alnylam Pharmaceuticals Inc. Profile
5.2.2 Alnylam Pharmaceuticals Inc. Main Business
5.2.3 Alnylam Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.2.4 Alnylam Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.2.5 Alnylam Pharmaceuticals Inc. Recent Developments
5.3 Applied Genetic Technologies Corporation
5.3.1 Applied Genetic Technologies Corporation Profile
5.3.2 Applied Genetic Technologies Corporation Main Business
5.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.3.4 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.3.5 Arrowhead Pharmaceuticals Inc. Recent Developments
5.4 Arrowhead Pharmaceuticals Inc.
5.4.1 Arrowhead Pharmaceuticals Inc. Profile
5.4.2 Arrowhead Pharmaceuticals Inc. Main Business
5.4.3 Arrowhead Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.4.4 Arrowhead Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.4.5 Arrowhead Pharmaceuticals Inc. Recent Developments
5.5 Carolus Therapeutics Inc.
5.5.1 Carolus Therapeutics Inc. Profile
5.5.2 Carolus Therapeutics Inc. Main Business
5.5.3 Carolus Therapeutics Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.5.4 Carolus Therapeutics Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.5.5 Carolus Therapeutics Inc. Recent Developments
5.6 Cevec Pharmaceuticals GmbH
5.6.1 Cevec Pharmaceuticals GmbH Profile
5.6.2 Cevec Pharmaceuticals GmbH Main Business
5.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.6.4 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.6.5 Cevec Pharmaceuticals GmbH Recent Developments
5.7 Dicerna Pharmaceuticals Inc.
5.7.1 Dicerna Pharmaceuticals Inc. Profile
5.7.2 Dicerna Pharmaceuticals Inc. Main Business
5.7.3 Dicerna Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.7.4 Dicerna Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.7.5 Dicerna Pharmaceuticals Inc. Recent Developments
5.8 Digna Biotech, S.L.
5.8.1 Digna Biotech, S.L. Profile
5.8.2 Digna Biotech, S.L. Main Business
5.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.8.4 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.8.5 Digna Biotech, S.L. Recent Developments
5.9 Editas Medicine Inc.
5.9.1 Editas Medicine Inc. Profile
5.9.2 Editas Medicine Inc. Main Business
5.9.3 Editas Medicine Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.9.4 Editas Medicine Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.9.5 Editas Medicine Inc. Recent Developments
5.10 Grifols, S.A.
5.10.1 Grifols, S.A. Profile
5.10.2 Grifols, S.A. Main Business
5.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.10.4 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.10.5 Grifols, S.A. Recent Developments
5.11 Inhibrx
5.11.1 Inhibrx Profile
5.11.2 Inhibrx Main Business
5.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.11.4 Inhibrx Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.11.5 Inhibrx Recent Developments
5.12 Intellia Therapeutics Inc.
5.12.1 Intellia Therapeutics Inc. Profile
5.12.2 Intellia Therapeutics Inc. Main Business
5.12.3 Intellia Therapeutics Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.12.4 Intellia Therapeutics Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.12.5 Intellia Therapeutics Inc. Recent Developments
5.13 International Stem Cell Corporation
5.13.1 International Stem Cell Corporation Profile
5.13.2 International Stem Cell Corporation Main Business
5.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.13.4 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.13.5 International Stem Cell Corporation Recent Developments
5.14 Ionis Pharmaceuticals Inc.
5.14.1 Ionis Pharmaceuticals Inc. Profile
5.14.2 Ionis Pharmaceuticals Inc. Main Business
5.14.3 Ionis Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.14.4 Ionis Pharmaceuticals Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.14.5 Ionis Pharmaceuticals Inc. Recent Developments
5.15 Kamada Ltd.
5.15.1 Kamada Ltd. Profile
5.15.2 Kamada Ltd. Main Business
5.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.15.4 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.15.5 Kamada Ltd. Recent Developments
5.16 Polyphor Ltd.
5.16.1 Polyphor Ltd. Profile
5.16.2 Polyphor Ltd. Main Business
5.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.16.4 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.16.5 Polyphor Ltd. Recent Developments
5.17 ProMetic Life Sciences Inc.
5.17.1 ProMetic Life Sciences Inc. Profile
5.17.2 ProMetic Life Sciences Inc. Main Business
5.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.17.4 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.17.5 ProMetic Life Sciences Inc. Recent Developments
5.18 rEVO Biologics Inc.
5.18.1 rEVO Biologics Inc. Profile
5.18.2 rEVO Biologics Inc. Main Business
5.18.3 rEVO Biologics Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.18.4 rEVO Biologics Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.18.5 rEVO Biologics Inc. Recent Developments
5.19 Sangamo BioSciences Inc.
5.19.1 Sangamo BioSciences Inc. Profile
5.19.2 Sangamo BioSciences Inc. Main Business
5.19.3 Sangamo BioSciences Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.19.4 Sangamo BioSciences Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.19.5 Sangamo BioSciences Inc. Recent Developments
6 North America
6.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Alpha- Antitrypsin Deficiency Treatment Market Dynamics
11.1 Alpha- Antitrypsin Deficiency Treatment Industry Trends
11.2 Alpha- Antitrypsin Deficiency Treatment Market Drivers
11.3 Alpha- Antitrypsin Deficiency Treatment Market Challenges
11.4 Alpha- Antitrypsin Deficiency Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
